

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: September 25, 2003

Page **1**

6

Atty. Dkt. No.	M#	Client Ref.
	037003-0280609	2000-30-0154A
Applicant:	Grillo-Lopez	RECEIVED
Appln. No.:	09/840,872	OCT 01 2003
Filing Date:	April 25, 2001	TECH CENTER 1600/2900
Examiner:	Gary B. Nickol	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
GW	AR	4,348,376	09/1982	Goldenberg	424	1	
	BR	4,454,106	06/1984	Gansow, et al.	424	1.1	
	CR	4,460,559	07/1984	Goldenberg	424	1.1	
	DR	4,472,509	09/1984	Gansow, et al.	436	548	
	ER	4,665,077	05/1987	Stringfellow, et al.	514	269	
	FR	4,816,567	03/1989	Cabilly, et al.	530	387	
	GR	4,831,175	05/1989	Gansow, et al.	558	17	
	HR	5,114,721	05/1992	Cohen, et al.	424	534	
	IR	5,116,964	05/1992	Capon, et al.	536	27	
	JR	5,182,107	01/1993	Friden	424	85.91	
	KR	5,500,362	03/1996	Robinson, et al.	435	7.23	
	LR	5,595,721	01/1997	Kaminski, et al.	424	1.49	
	MR	5,674,492	10/1997	Armitage, et al.	424	144.1	
	NR	5,677,180	10/1997	Robinson, et al.	435	328	
	OR	5,693,780	12/1997	Newman, et al.	536	23.53	
	PR	5,736,137	04/1998	Anderson, et al.	424	133.1	
	QR	5,747,037	05/1998	Noelle, et al.	424	154.1	
	RR	5,776,456	07/1998	Anderson, et al.	424	133.1	
	SR	5,801,227	09/1998	Fanslow, III et al.	530	388.73	
	TR	5,821,337	10/1998	Carter, et al.	530	387.3	
	UR	5,833,987	11/1998	Noelle, et al.	424	154.1	
	VR	5,843,398	12/1998	Kaminski, et al.	424	1.49	
	WR	5,843,439	12/1998	Anderson, et al.	424	133.1	
	XR	5,874,082	02/1999	de Boer	424	153.1	
	YR	5,874,085	02/1999	Mond, et al.	424	195.11	
	ZR	5,876,718	03/1999	Noelle, et al.	424	154.1	
	AAR	5,716,614	02/1998	Katz, et al.	424	94.3	
	BBR	6,001,358	12/1999	Black, et al.	424	154.1	
	CCR	6,183,744	02/2001	Goldenberg	424	131.1	
	DDR	6,306,393	10/2001	Goldenberg	424	141.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
GW	EER	0 340 109 B1	05/1997	EP	Steinman, et al.				
	FFR	0 404,097 B1	09/1996	EP	Bosslet, et al.				
	GGR	0 555 880 A2	08/1993	EP	Aruffo, et al.				
	HHR	0 555 880 A3	08/1993	EP	Aruffo, et al.				

RECEIVE

OCT 11 2003
TECH CENTER 1600/2900

GN	IIR	WO 90/0815	07/1990	WO	Reinherz, et al.				
O P E	JJR	WO 90/11294	10/1990	WO	Howell, et al.				
SEP 26 2003	KKR	WO 91/01133	02/1991	WO	Goldstein, et al.				
PATENT & TRADEMARKS OFFICE	L R	WO 93/11161	06/1993	WO	Whitlow, et al.				
	MMR	WO 94/11026	05/1994	WO	Anderson, et al.				
	NNR	WO 95/06666	03/1995	WO	Noelle, et al.				
	OOT	WO 95/17202	06/1995	WO	Armitage, et al.				
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
(W)	PPR	Abrey et al., Combination chemotherapy in primary central nervous system lymphoma," (abstract) Proc. Am. Soc. Clin. Onc. (1999)							
	QQR	Abrey et al., Long-term survival in primary CNS lymphoma, J. Clin. Oncol. 16: 859-63 (1998)							
	RRR	Armitage et al., Molecular and biological characterization of a murine ligand for CD40, Nature 357:80-82 (1992)							
	SSR	Behr et al., Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, Clin. Cancer Res. 5: 3304s-14s (1999)							
	TTR	Bejcek et al., Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen, Cancer Res. 55: 2346-51 (1995)							
	UUR	Benoit et al., Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, Immunopharmacology 35: 129-139 (1996)							
	VVR	Berinstein et al., Association of serum rituximab (IDE-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann. Oncol. 9: 995-1001 (1998)							
	WWR	Blay et al., High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series, J. Clin. Oncol. 16: 864-871 (1998)							
	XXR	Bolognesi et al., Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): <i>in vitro</i> and <i>in vivo</i> studies, Br. J. Haematol. 101: 179-88 (1998)							
	YYR	Capon et al., Designing CD4 immunoadhesins for AIDS therapy, Nature 337: 525-531 (1989)							
	ZZR	Chamberlain et al., Primary central nervous system lymphoma: a role for adjuvant chemotherapy, J. Neuro. Oncol. 14: 271-275 (1992)							
	AAAR	Cheng et al., Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma, Cancer 82: 1946-51 (1998)							
	BBBBR	Clodi et al., Unbalanced expression of Fas and CD40 in mantle cell lymphoma, Brit. J. Haematol. 103: 217-9 (1998)							
	CCCR	Clynes et al., Fc receptors are required in passive and active immunity to melanoma, PNAS (USA) 95:652-656 (1998)							
	DDDR	Coiffier et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study, Blood 92: 1927-1932 (1998)							
	EEER	Czuczman et al., Treatment of patients with low-grade B-cell lymphoma with the combinations of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, J. Clin. Oncol. 17: 268-76 (1999)							
	FFFR	DeAngelis et al., "Primary Central Nervous System Lymphoma," IN CANCER: PRINCIPLES & PRACTICE OF ONCOLOGY 2233-2242 (DeVita et al., eds. 1997).							
	GGGR	Deguchi et al., Retention of biologic activity of human epidermal growth factor following conjugation of a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker, Bioconjug. Chem. 10: 32-37 (1999)							
	HHHR	Endo, Gan To Kagaku Ryohe 26: 744-748 (1999)							

RECEIVED

OCT 01 2003
TECH CENTER 1600/2900

GW O I P SEP 26 2003 PATENT & TRADEMARK OFFICE	1IIR	Finé et al., Primary central nervous system lymphoma, <u>Ann. Intern. Med.</u> 119: 1093-1104 (1993)	
	JJF SC 84 K KKR	Flavell et al., Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone, <u>Int. J. Cancer</u> 62: 337-44 (1995)	
	LLLR	Freilich et al., Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients, <u>Neurology</u> 46: 435-439 (1996)	
	MMMR	Funakoshi et al., Inhibition of human B-cell lymphoma growth by CD40 stimulation, <u>Blood</u> 83: 2787-2794 (1994)	
	NNNR	Funakoshi et al., Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, <u>J. Immunother. Emphasis Tumor Immunol.</u> 19: 93-101 (1996)	
	OOOR	Ghetie et al., Anti-CD19 antibodies inhibit the function of the P-gp pump in multigrug-resistant B lymphoma cells, <u>Clin. Cancer Res.</u> 5: 3920-7 (1999)	
	PPPR	Green et al., Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS, <u>Virology</u> 241: 260-268 (1998)	
	QQQR	Hekman et al., Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody <u>Cancer Immunol. Immunother.</u> 32:364-372 (1991)	
	RRRR	Herrlinger et al., Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin, <u>J. Neurooncol.</u> 40: 1-9 (1998)	
	SSSR	Hollenbaugh et al., The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, <u>EMBO J.</u> 11:4313-4321 (1992)	
	TTTR	Hollinger et al., "Diabodies": small bivalent and bispecific antibody fragments, <u>Proc. Nad. Acad. Sci. USA</u> , 90:6444-6448 (1993).	
	UUUR	Huwylter et al., Brain drug delivery of small molecules using immunoliposomes, <u>Proc. Nat'l Acad. Sci. USA</u> 93: 14164-14169 (1996)	
	VVVR	Illidge et al., The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma, <u>Blood</u> 94: 233-43 (1999)	
	WWWR	Janeway, Immunotherapy by peptides, <u>Nature</u> , 341: 482 (1989)	
	XXXR	Johnson et al., Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system, <u>Blood</u> 82: 1848-1857 (1993)	
	YYYR	Kiesel et al., Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytosis, <u>Leukemia Research</u> 11, 12: 1119 (1987)	
	ZZZR	Kramer et al., Tc-99m LL-2 Fab' monoclonal antibody imaging in acquired immune deficiency syndrome-related lymphoma, <u>Cancer</u> 80: 2469-2477 (1997)	
	AAAAR	Kroll et al., Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means, <u>Neurosurgery</u> 42: 1083-99 (1998)	
	BBBBR	Ledbetter et al., Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency, <u>Circ. Shock</u> 44: 67-72 (1994)	

RECEIVED

OCT 01 2003
TECH CENTER 1800/2300

10/26/03	CCCCR	Ledermann <i>et al.</i> , Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), <u>J. Exp. Med.</u> 175: 1091-1101 (1992)	
10/26/03	DDDDR	Leget <i>et al.</i> , Use of rituximab, the new FDA-approved antibody, <u>Curr. Opin. Oncol.</u> 10: 548-551 (1998)	
10/26/03	EEER	Lesser <i>et al.</i> , The chemotherapy of adult primary brain tumor, <u>Cancer Treat. Rev.</u> 19: 261-281 (1993)	
	FFFFR	Li <i>et al.</i> , Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy, <u>Cancer Immunol. Immunother.</u> 47: 121-30 (1998)	
	GGGGR	Lieberman <i>et al.</i> , Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion, <u>J. Neurosurg.</u> 82: 1021-1029 (1995)	
	HHHHR	Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, <u>J. Exp. Med.</u> 178: 721-730 (1991)	
	IIIR	Maloney <i>et al.</i> , IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, <u>Blood</u> 90: 2188-2195 (1997)	
	JJJJR	Mansfield <i>et al.</i> , Characterization of RFB4-pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies, <u>Bioconjug. Chem.</u> 7: 557-63 (1996)	
	KKKKR	Mason <i>et al.</i> , ¹¹¹ Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases, <u>Neurology</u> 50: 438-444 (1998)	
	LLLLR	McLaughlin <i>et al.</i> , Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, <u>J. Clin. Oncol.</u> 16: 2825-2833 (1998)	
	MMMMR	McLaughlin <i>et al.</i> , Clinical status and optimal use of rituximab for B-cell lymphomas, <u>Oncology (Huntingt)</u> 12: 1763-1777 (1998)	
	NNNNR	Monjour <i>et al.</i> , Lymphomes malins non Hodgkiens primitifs du système nerveux central, <u>Rev. Neurol. (Paris)</u> 148: 589-600 (1992)	
10/26/03	OOOR	Morrison <i>et al.</i> , Genetically engineered antibody molecules, <u>Adv. Immunol.</u> 44: 65-92 (1988)	
10/26/03	PPPRR	Morrison <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-6855 (1984)	
	QQQQR	Murphy <i>et al.</i> , Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes, <u>Blood</u> 86: 1946-1953 (1995)	
	RRRRR	Nguyen <i>et al.</i> , IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, <u>Eur. J. Haematol.</u> 62: 76-82 (1999)	
	SSSSR	Offner <i>et al.</i> , T Cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis, <u>Science</u> 251: 430-432 (1991)	
	TTTTR	O'Neill <i>et al.</i> , Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?, <u>Int'l J. Radiation Oncol. Biol. Phys.</u> 33: 663-673 (1995)	

RECEIVED
OCT 01 2003
TECH CENTER 16002900

	UUUR	Orlowski <i>et al.</i> , Hodgkin's disease with leptomeningeal involvement, <u>Cancer</u> 53: 1833-1835 (1984)		
	VVVVR	Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <u>Molec. Immun.</u> 28: 489-498 (1991)		
	WWWWWR	Padlan, Anatomy of the antibody molecule, <u>Molec. Immun.</u> 31: 169-217 (1994)		
	XXXXR	Partridge <i>et al.</i> , Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, <u>Pharm. Res.</u> 15: 576-82 (1998)		
	YYYYR	Pastan <i>et al.</i> , Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model, <u>Proc. Nat'l Acad. Sci. USA</u> 92: 2765-2769 (1995)		
	ZZZZR	Perez-Jaffe <i>et al.</i> , Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry, <u>Diagn. Cytopathol.</u> 20:219-223 (1999)		
	AAAAAR	Piro <i>et al.</i> , Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, <u>Ann. Oncol.</u> 10: 655-61 (1999)		
	BBBBBR	Press <i>et al.</i> , Monoclonal antibody 1F2 (Anti-CD20) serotherapy of human B cell lymphomas, <u>Blood</u> 69: 584-591 (1987)		
	CCCCCR	Ravetch and Kinet, Fc receptors, <u>Annu. Rev. Immunol.</u> 9:457-92 (1991)		
	DDDDDR	Reni <i>et al.</i> , Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature, <u>Ann. Oncol.</u> 8: 227-234 (1997)		
	EEEEER	Sandor <i>et al.</i> , Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma, <u>J. Clin. Oncol.</u> 16: 3000-3006 (1998)		
	FFFFFR	Schabert <i>et al.</i> , Diagnose und therapie der meningosis neoplastica, <u>Nervenarzt</u> 63: 317-27 (1992)		
	GGGGGR	Stamenkovic <i>et al.</i> , A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, <u>EMBO J.</u> 8: 1403-1410 (1989)		
	HHHHHR	Stone <i>et al.</i> , A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma, <u>Blood</u> 88: 1188-97 (1996)		
	IIIIIR	Strauchen <i>et al.</i> , Chemotherapy in the management of intraocular lymphoma, <u>Cancer</u> 63: 1918-21 (1989)		
	JJJJJR	Tutt <i>et al.</i> , Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors, <u>J. Immunol.</u> 161: 3176-3185 (1998)		
	KKKKKR	Valentine <i>et al.</i> , B3.9 Structure and function of the B-cell specific 35-37 kDa CD20 protein, In: <u>Leukocyte Typing III</u> (McMichael, Ed., p. 440, Oxford University Press (1987)		
	LLLLLR	Valle <i>et al.</i> , Activation of human B lymphocytes through CD40 and interleukin 4, <u>Eur. J. Immunol.</u> 19: 1463-1467 (1989)		
	MMMMMR	Valluri <i>et al.</i> , Combination treatment of intraocular lymphoma, <u>Retina</u> 15: 125-9 (1995)		

RECEIVED

OCT 01 2003
TECH CENTER 1600/2900

<i>GN</i>	NNNNNR	van Besien <i>et al.</i> , Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma, <u>Blood</u> 91: 1178-1184 (1998)	
<i>O F F I C E</i> <i>SEP 23 2003</i> <i>PATENT & TRADEMARK OFFICE</i>	OOOOOR	Verhoeven <i>et al.</i> , Reshaping human antibodies: Grafting an antilysozyme activity, <u>Science</u> 239: 1534-1536 (1988)	
<i>PPPPR</i>	PPPPR	Vlasveld <i>et al.</i> , Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19, <u>Cancer Immunol. Immunother.</u> 40:37-47(1995)	
<i>QQQQQR</i>	QQQQQR	Wang <i>et al.</i> , Induction of bcl-x by CD40 engagement rescues slg-induced apoptosis in murine B cells, <u>J. Immunol.</u> 155: 3722-5 (1995)	
<i>RRRRRR</i>	RRRRRR	White <i>et al.</i> , Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma, <u>Pharm. Sci. Technol.</u> Today 2: 95-101 (1999)	
<i>SSSSSR</i>	SSSSSR	Wu <i>et al.</i> , Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody, <u>Drug. Metabol. Dispos.</u> 26: 937-9 (1998)	
<i>TTTTTR</i>	TTTTTR	Youle, Immunotoxins for central nervous system malignancy, <u>Semin. Cancer Biol.</u> 7: 65-70 (1996)	
<i>UUUUUR</i>	UUUUUR		
<i>VVVVVR</i>	VVVVVR		

Examiner

Jameson Miller

Date Considered:

12/10/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.